Soleno Therapeutics, Inc. is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases.
We are committed to developing safe and effective therapeutic products that improve the lives of patients living with complex, life-threatening rare diseases with unmet medical needs.
Meet our team of advisors who lend their invaluable expertise and knowledge directly to our research and development process.
Dr. Butler is a Professor of Psychiatry and Pediatrics and Director, Division of Research, Department of Psychiatry and Behavioral Sciences at University of Kansas Medical Center. His research interests include the genetics of obesity with emphasis on Prader-Willi syndrome and obesity-related disorders, autism, psychiatric and behavioral genetics, genotype-phenotype correlations and the natural history and delineation of rare and uncommon clinical genetics syndromes. He has conducted research on Prader-Willi, Angelman and Fragile X syndromes, the genetics of autism and obesity and delineation of genetic disorders.
He is board-certified in Clinical Genetics and Clinical Cytogenetics and became a Founding Fellow of the American College of Medical Genetics and Genomics (ACMG) in 1993. He is Chairperson of the Scientific Advisory Board of the Prader-Willi Syndrome Association (USA) and received the Lifetime Achievement Award in 2008. He has published over 400 research articles, multiple book chapters and edited several journal issues and two textbooks.
Dr. Driscoll is a Professor of Pediatrics, Professor of Genetics, and John T. and Winifred M. Hayward Professor of Genetics Research in the Department of Pediatrics, Division of Genetics and Metabolism at University of Florida, College of Medicine. His research interests are focused in three interrelated areas that combine his clinical and basic science expertise; Genomic imprinting/Epigenetics; Prader-Willi syndrome; and Early-onset morbid obesity. His laboratory was the first to propose and demonstrate a whole new class of mutations now called imprinting defects. This type of mutation has since been found in several other diseases and cancers. He developed systems for the rapid diagnosis of Prader-Willi syndrome and several other imprinted disorders.
Dr. Driscoll is board-certified in Medical Genetics (Clinical, Molecular and Cytogenetics) and Pediatrics. He is the Chairperson of the Clinical and Scientific Advisory Board of the International Prader-Willi Syndrome Organization (IPWSO). Dr. Driscoll is also the Chairperson of the Clinical Advisory Board of the Prader-Willi Syndrome Association (USA).
Dr. Dykens is a Professor of Psychology and Human Development, Professor of Psychiatry and Professor of Pediatrics at Vanderbilt University. She is an Annette Schaffer Eskind Professor and Director of the Vanderbilt Kennedy Center for Research on Human Development, and Co-Director for the University Center for Excellence in Developmental Disabilities. Her research examines psychopathology and areas of strength in persons with intellectual and developmental disabilities, especially those with genetic syndromes. Her studies focus on the development and correlates of psychopathology and behavioral problems in Prader-Willi syndrome, Williams syndrome, and Down syndrome. She also examines profiles of neurocognitive and adaptive strengths and weaknesses in these disorders, and how these unusual profiles refine treatment and shed light on normal development.
Dr. Dykens serves on the Scientific Advisory Board of the Prader-Willi Syndrome Association (USA). She serves on the Board of Directors of Special Olympics International. She has authored more than 220 publications, including 3 books.
Developing novel therapeutics for the treatment of rare diseases.
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2019 Financial Results
Soleno Therapeutics Announces Closing of $15.4 Million Public Offering of Common Stock